多替阿巴拉米片在什么时候上市的?
Also called Suimeikai, it was approved by the US FDA in 2014 for the treatment of adults and adolescents over 12 years old (weight not less than 40 kilograms) infected with human immunodeficiency virus (HIV, also called AIDS).
On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation dolutea palamid tablets were officially launched in mainland China. Dolutegra abalami tablets have officially begun to provide new treatment options for HIV patients in my country. This is the best-selling drug for the treatment of AIDS in my country in the past five years and plays an important role in the field of AIDS treatment.
Dolutegravir tablets are a compound preparation that mainly contains three ingredients, namely dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. One tablet is a complete treatment regimen. Moreover, the use of Dolutegra Abalamid Tablets is simple. One tablet a day can achieve the effect of cocktail therapy without food restrictions, which greatly improves patients' medication compliance. In terms of therapeutic effect, it can also significantly inhibit the virus, has smaller side effects, and is less likely to develop drug resistance.
Because the ingredients in dolutegravir may cause hypersensitivity reactions, patients should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products, regardless of race. Both abacavir and dolutegravir carry the risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. Patients should pay close attention to their own conditions and stop taking the drug and seek medical treatment immediately if hypersensitivity occurs.
Currently, it has been approved for marketing in 50 countries and regions, and more and more HIV patients will benefit from it. In addition to the original drug, doptabalamid tablets are also launched in India, with a lower price. Patients in need can also consult the medical companion travel service for specific prices.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)